Literature DB >> 21315756

Alzheimer's disease and age-related memory decline (preclinical).

Alvin V Terry1, Patrick M Callahan, Brandon Hall, Scott J Webster.   

Abstract

An unfortunate result of the rapid rise in geriatric populations worldwide is the increasing prevalence of age-related cognitive disorders such as Alzheimer's disease (AD). AD is a devastating neurodegenerative illness that is characterized by a profound impairment of cognitive function, marked physical disability, and an enormous economic burden on the afflicted individual, caregivers, and society in general. The rise in elderly populations is also resulting in an increase in individuals with related (potentially treatable) conditions such as "Mild Cognitive Impairment" (MCI) which is characterized by a less severe (but abnormal) level of cognitive impairment and a high-risk for developing dementia. Even in the absence of a diagnosable disorder of cognition (e.g., AD and MCI), the perception of increased forgetfulness and declining mental function is a clear source of apprehension in the elderly. This is a valid concern given that even a modest impairment of cognitive function is likely to be associated with significant disability in a rapidly evolving, technology-based society. Unfortunately, the currently available therapies designed to improve cognition (i.e., for AD and other forms of dementia) are limited by modest efficacy and adverse side effects, and their effects on cognitive function are not sustained over time. Accordingly, it is incumbent on the scientific community to develop safer and more effective therapies that improve and/or sustain cognitive function in the elderly allowing them to remain mentally active and productive for as long as possible. As diagnostic criteria for memory disorders evolve, the demand for pro-cognitive therapeutic agents is likely to surpass AD and dementia to include MCI and potentially even less severe forms of memory decline. The purpose of this review is to provide an overview of the contemporary therapeutic targets and preclinical pharmacologic approaches (with representative drug examples) designed to enhance memory function.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315756      PMCID: PMC3113643          DOI: 10.1016/j.pbb.2011.02.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  377 in total

1.  The physiological role of 5-HT2A receptors in working memory.

Authors:  Graham V Williams; Srinivas G Rao; Patricia S Goldman-Rakic
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.

Authors:  A I Levey; C A Kitt; W F Simonds; D L Price; M R Brann
Journal:  J Neurosci       Date:  1991-10       Impact factor: 6.167

3.  Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice.

Authors:  Zhi-fei Wang; Li-li Tang; Han Yan; Yu-jun Wang; Xi-can Tang
Journal:  Pharmacol Biochem Behav       Date:  2006-05-09       Impact factor: 3.533

Review 4.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

5.  Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo.

Authors:  C A Briggs; D J Anderson; J D Brioni; J J Buccafusco; M J Buckley; J E Campbell; M W Decker; D Donnelly-Roberts; R L Elliott; M Gopalakrishnan; M W Holladay; Y H Hui; W J Jackson; D J Kim; K C Marsh; A O'Neill; M A Prendergast; K B Ryther; J P Sullivan; S P Arneric
Journal:  Pharmacol Biochem Behav       Date:  1997 May-Jun       Impact factor: 3.533

6.  Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles.

Authors:  Abdelouahid Samadi; José Marco-Contelles; Elena Soriano; Mónica Alvarez-Pérez; Mourad Chioua; Alejandro Romero; Laura González-Lafuente; Luis Gandía; José M Roda; Manuela G López; Mercedes Villarroya; Antonio G García; Cristóbal de Los Ríos
Journal:  Bioorg Med Chem       Date:  2010-07-03       Impact factor: 3.641

7.  GABA(A) receptor antagonists enhance cortical acetylcholine release induced by 5-HT(3) receptor blockade in freely moving rats.

Authors:  Mónica Diez-Ariza; Mónica García-Alloza; Berta Lasheras; Joaquín Del Río; María Javier Ramírez
Journal:  Brain Res       Date:  2002-11-22       Impact factor: 3.252

Review 8.  Nicotine's effect on neural and cognitive functioning in an aging population.

Authors:  K N Murray; N Abeles
Journal:  Aging Ment Health       Date:  2002-05       Impact factor: 3.658

9.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation.

Authors:  M Ruat; E Traiffort; J M Arrang; J Tardivel-Lacombe; J Diaz; R Leurs; J C Schwartz
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

Review 10.  Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties.

Authors:  Cornelis J Van der Schyf; Silvia Mandel; Werner J Geldenhuys; Tamar Amit; Yael Avramovich; Hailin Zheng; Mati Fridkin; Shunit Gal; Orly Weinreb; Orit Bar Am; Yotam Sagi; Moussa B H Youdim
Journal:  Curr Alzheimer Res       Date:  2007-12       Impact factor: 3.498

View more
  23 in total

Review 1.  Huperzine A for mild cognitive impairment.

Authors:  Jirong Yue; Bi Rong Dong; Xiufang Lin; Ming Yang; Hong Mei Wu; Taixiang Wu
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

2.  Positive allosteric modulator of α7 nicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates.

Authors:  Patrick M Callahan; Elizabeth J Hutchings; Nancy J Kille; James M Chapman; Alvin V Terry
Journal:  Neuropharmacology       Date:  2012-11-17       Impact factor: 5.250

3.  Effects of tobacco smoke constituents, anabasine and anatabine, on memory and attention in female rats.

Authors:  Edward D Levin; Ian Hao; Dennis A Burke; Marty Cauley; Brandon J Hall; Amir H Rezvani
Journal:  J Psychopharmacol       Date:  2014-08-13       Impact factor: 4.153

4.  Silymarin ameliorates memory deficits and neuropathological changes in mouse model of high-fat-diet-induced experimental dementia.

Authors:  Amit Kumar; Amteshwar S Jaggi; Rupinder K Sodhi; Nirmal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-28       Impact factor: 3.000

Review 5.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

6.  HO-1 dependent antioxidant effects of ethyl acetate fraction from Physalis alkekengi fruit ameliorates scopolamine-induced cognitive impairments.

Authors:  Md Moniruzzaman; Young-Won Chin; Jungsook Cho
Journal:  Cell Stress Chaperones       Date:  2018-03-15       Impact factor: 3.667

7.  Timosaponin B-II ameliorates scopolamine-induced cognition deficits by attenuating acetylcholinesterase activity and brain oxidative damage in mice.

Authors:  Xu Zhao; Chunmei Liu; Yu Qi; Lina Fang; Jie Luo; Kaishun Bi; Ying Jia
Journal:  Metab Brain Dis       Date:  2016-07-22       Impact factor: 3.584

8.  Effect of thimerosal on the neurodevelopment of premature rats.

Authors:  Yan-Ni Chen; Jue Wang; Jie Zhang; Su-Jiao Li; Li He; Dong-Dong Shao; Hui-Ying Du
Journal:  World J Pediatr       Date:  2013-11-14       Impact factor: 2.764

Review 9.  New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.

Authors:  Nigel H Greig; Marcella Reale; Ada M Tata
Journal:  Recent Pat CNS Drug Discov       Date:  2013-08

10.  Thymoquinone prevents β-amyloid neurotoxicity in primary cultured cerebellar granule neurons.

Authors:  Norsharina Ismail; Maznah Ismail; Musalmah Mazlan; Latiffah Abdul Latiff; Mustapha Umar Imam; Shahid Iqbal; Nur Hanisah Azmi; Siti Aisyah Abd Ghafar; Kim Wei Chan
Journal:  Cell Mol Neurobiol       Date:  2013-10-08       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.